Eli Lilly Buys 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 Billion, the Largest Psychedelic Deal Yet
Eli Lilly, the world’s largest pharmaceutical company, confirmed Thursday morning that it will acquire AtaiBeckley in a deal worth up to $3.8 billion. The purchase hands Lilly the company’s lead candidate, an intranasal form of 5-MeO-DMT for treatment resistant depression that is now entering Phase 3 trials. No acquisition in psychedelic medicine has come close […]
Read More